Know Cancer

forgot password

Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of Hepatocellular Carcinoma: a Randomized Controlled Trial

Phase 1/Phase 2
18 Years
75 Years
Not Enrolling
Hepatocellular Carcinoma

Thank you

Trial Information

Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of Hepatocellular Carcinoma: a Randomized Controlled Trial

1. Background

Hepatocellular carcinoma (HCC) is the second commonest cause of cancer death in Hong
Kong and the majority are hepatitis B related. Hepatic resection has remained the only
therapeutic option that can offer these patients a chance of long-term survival.
Although the safety of hepatectomy has improved, postoperative recurrences are
frequent. Depending on the size of the primary tumors, recent reports from Japan,
France and Hong Kong1 showed that the postoperative recurrence rate was 20 to 64% at
one year and 57 to 81% at 3 years.

While the hepatic remnant is the predominant site of recurrence, involvement of
extrahepatic organs was not infrequent. There are three possible mechanisms for the
development of recurrent disease:

i) residual tumor cells due to an inadequate resection margin ii) subclinical
metastasis that occurs before or during hepatic resection iii) metachronous
multicentric hepatocarcinogenesis which may be related to the underlying
necroinflammation of chronic active hepatitis and oncogenic activities of hepatitis

The surgeon's attempt to prevent recurrence by more extensive resection is prohibited
by the need to preserve hepatic function. Futhermore, even a major hepatic resection
cannot guarantee freedom from recurrence since metachronous multicentric tumors can
develop in the entire liver. Theorectically, total hepatectomy and liver
transplantation removes both the subclinical metastases in the liver and prevent
metachronous lesions. Unfortunately, with immunosuppressive therapy, recurrences are
frequent and tumors grow more rapidly, thus, illustrating the importance of the host
immune surveillance in preventing the development of recurrence.

The use of postoperative regional and systemic chemotherapy has been reported. Although
retrospective studies have shown encouraging results, there are only limited number of
prospective trials. The favourable result of the use of oral
1-hexylcarbomyl-5-fluorouracil in a multi-center trial as reported by Yamamoto and
colleagues was questionable since treatment was suspended due to side-effects in 44% of
the patients. Our single-center prospective randomised study performed at Queen Mary
Hospital (QMH) using a combination of transarterial chemoembolisation and systemic
epirubicin showed a higher extrahepatic recurrence rate and worse outcome with the use
of adjuvant chemotherapy. The reasons for the failure of adjuvant chemotherapy include:

i) HCC is slow-growing and hence cytotoxic drug resistant. ii) the associated liver
cirrhosis limits the maximum tolerated intensity of chemotherapy iii) the anticancer
agents may adversely affect the host immunity

2. Interferon alpha-2b

Interferon alpha-2b is a recombinant form of human interferon. Interferons are
cytokines possessing anti-viral, anti-proliferative and immunodulatory effects.
Interferon may halt the replication of both hepatitis B and hepatitis C virus, thus,
reducing the severity of the chronic active hepatitis. The histologic activity of
chronic active hepatitis is an important risk factor for recurrence related to
metachronous multicentric hepatocarcinogenesis and the use of interferon has been shown
to reduce the incidence of HCC in patients with cirrhosis due to hepatitis C and
possibly hepatitis B.

Interferon has a powerful anti-proliferative effect on hepatoma cell-line PLC/PRF/5 in
a dose-dependent manner both in-vitro and in-vivo. The use of interferon has been
applied to patients with inoperable HCC with a tumour regression rate and survival rate
superior to that of placebo-control or chemotherapeutic agents such as doxorubicin.

Peripheral blood mononuclear cells from patients with HCC have considerably reduced
cytotoxicity against hepatoma cell lines. Interferon has been shown to normalise the
T-lymphocyte subpopullation and enhance the cytotoxic activity against an
HBsAg-producing hepatoma cell line in-vitro.

3. Interferon adverse effects

Interferon alpha-2b is registered for treatment of HCC and chronic hepatitis B in Hong
Kong. In patients with unresectable HCC, interferon has a much lower incidence of fatal
side-effects when compared to doxorubicin. Most patients experience flu-like symptoms
including fever, headache, fatigue and myalgia which usually subside spontaneously with
continuation of treatment. Less common but more serious adverse effects include
alopecia, leukopenia, thrombocytopenia, depression, irritability, and mental
deterioration. The adverse effects are dose-dependent and the majority are reversible
with a reduction in dosage. The use of high-dose interferon has been well-tolerated in
clinical trials involving patients with unresectable HCC.

4. Rationale

Interferon has anti-viral, anti-proliferative and immunodulatory activities. It has been
used clinically in the treatment of unresectable HCC as well as viral hepatitis B and C. It
can potentially reduce the incidence of recurrence due to residual tumour cells or
metachronous multicentric disease in patients after resection for HCC.

Inclusion Criteria:

All patients who undergo a curvative hepatic resection for HCC at the Department of
Surgery, Queen Mary Hospital are included. The criteria for curative resection include
all of the following :

i) Complete extirpation of disease as demonstrated by intraoperative ultrasonography
during surgery ii) Histologic evidence of a clear resection margin iii) No evidence of
residual disease in the liver remnant as demonstrated by spiral contrast-enhanced CT scan
one month after surgery

Exclusion Criteria:

i) patient refusal ii) age > 75 years old iii) hospital mortality iv) disease previously
treated by regional or systemic chemotherapy, hormonal therapy or immunotherapy v) poor
hepatic function:

1. presence of hepatic encephalopathy

2. presence of ascites not controlled by diuretics

3. history of variceal bleeding within last 3 months

4. total serum bilirubin > 50 umol/L

5. serum albumin < 30 g/L

6. prothrombin time prolonged for > 4 seconds vi) poor renal function with serum
creatinine > 180mol/L vii) Absolute neutrophil count < 1.5 x 109/L viii) Platelet
count < 75 x 109/L ix) poor performance status with European Cooperative Oncology
Group (ECOG) scale grade III or IV

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Occurrence of recurrent disease

Principal Investigator

Chung Mau Lo, MS

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department of Surgery, The University of Hong Kong


Hong Kong: Department of Health

Study ID:

EC 1018-98



Start Date:

January 2000

Completion Date:

December 2004

Related Keywords:

  • Hepatocellular Carcinoma
  • liver cancer
  • hepatectomy
  • survival
  • recurrence
  • Carcinoma
  • Carcinoma, Hepatocellular